UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 153

Sortiert nach

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: Whenever IQWiG and Federal Joint Committee disagree

Health economics review, 2019-12, Vol.9 (35), p.1-15, Article 35

2019

Link zum Volltext

Verfügbarkeit prüfen

Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?

Health policy (Amsterdam), 2020-09, Vol.124 (9), p.943-951

2020

Link zum Volltext

Verfügbarkeit prüfen

The Risky Business of Drug Development: The Final Say of National Hta Agencies on A Pharmaceutical's Benefit During The Last Stretch of An Expensive, Long-Lasting And Arduous Development Journey – As Illustrated By The Decisions Of Germany's Gemeinsamer Bundesausschuss (G-Ba)

Value in health, 2014-11, Vol.17 (7), p.A439-A439

2014

Link zum Volltext

Verfügbarkeit prüfen

Dilemma of Cross-Over Trials and Their Impact on Benefit Assessment In Oncology

Value in health, 2014-11, Vol.17 (7), p.A658-A658

2014

Link zum Volltext

Verfügbarkeit prüfen

Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer’s data sources

Annals of the rheumatic diseases, 2003-06, Vol.62 (6), p.544-550

2003

Link zum Volltext

Verfügbarkeit prüfen

PRM162 Appropriate Comparative Treatments for Early Benefit Assessment (EBA) in Germany. Comparing the Suggestions by the Joint Federal Committee (GBA) and the Pharmaceutical Companies

Value in health, 2012-11, Vol.15 (7), p.A490-A490

2012

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Post-Authorisation Measures From Regulatory Authorities With Additional Evidence Requirements From HTA Bodies in Germany

Value in health, 2014-11, Vol.17 (7), p.A427-A427

2014

Link zum Volltext

Verfügbarkeit prüfen

Multi-Dimensional Capture of Patient-Relevant Endpoints in Regulatory Trials and Health Technology Assessments in Oncology Two Years After Introduction of the German Amnog Health Care Reform

Value in health, 2013-11, Vol.16 (7), p.A575-A575

2013

Link zum Volltext

Verfügbarkeit prüfen

PHP148 Early Benefit Assessment (EBA) in Germany: Differences Between Pharmaceutical Companies' Claims and IQWiG Benefit Assessments

Value in health, 2012-11, Vol.15 (7), p.A315-A315

2012

Link zum Volltext

Verfügbarkeit prüfen

PRM5 Attribution of Benefit to the Three Disease Dimensions Mortality, Morbidity, Quality of Life Within Early Benefit Assessment (EBA) in Germany

Value in health, 2012-11, Vol.15 (7), p.A460-A460

2012

Link zum Volltext

Verfügbarkeit prüfen

Content comparison of health status measures for obesity based on the international classification of functioning, disability and health

International Journal of Obesity, 2006-12, Vol.30 (12), p.1791-1799

2006

Link zum Volltext

Verfügbarkeit prüfen

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

International Journal of Obesity, 2005-05, Vol.29 (5), p.517-523

2005

Link zum Volltext

Verfügbarkeit prüfen

Development and validation of a self-administered systemic sclerosis questionnaire (SySQ)

Rheumatology (Oxford, England), 1999-06, Vol.38 (6), p.535-542

1999

Link zum Volltext

Verfügbarkeit prüfen

Lipid-Lowering Medication for Secondary Prevention of Coronary Heart Disease in a German Outpatient Population: The Gap Between Treatment Guidelines and Real Life Treatment Patterns

Preventive medicine, 2002-07, Vol.35 (1), p.48-53

2002

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland

International Journal of Obesity, 2005-08, Vol.29 (8), p.975-982

2005

Link zum Volltext

Verfügbarkeit prüfen

PCN152 Patient-Relevant Endpoints (PRE) in Oncology - Current Issues in the Context of Early Benefit Assessment (EBA) in Germany: An Industry Perspective

Value in health, 2012-11, Vol.15 (7), p.A437-A437

2012

Link zum Volltext

Verfügbarkeit prüfen

Produktivitätskosten der rheumatoiden Arthritis in Deutschland : Kostenzusammensetzung und Prädiktion der Hauptkostenkomponenten

Zeitschrift für Rheumatologie, 2006-10, Vol.65 (6), p.527-534

2006

Link zum Volltext

Verfügbarkeit prüfen

Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis

Journal of rheumatology, 2001-03, Vol.28 (3), p.657

2001

Link zum Volltext

Verfügbarkeit prüfen

PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE

Value in health, 2019-11, Vol.22, p.S807-S807

2019

Link zum Volltext

Verfügbarkeit prüfen

PDG84 REVIEW OF RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) AT THE EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUNETHTA)

Value in health, 2019-11, Vol.22, p.S611-S611

2019

Link zum Volltext

Verfügbarkeit prüfen

Costs in rheumatology : results and lessons learned from the 'Hannover Costing Study'

Rheumatology international, 2006-06, Vol.26 (8), p.704-711

2006

Link zum Volltext

Verfügbarkeit prüfen

Direct costs related to rheumatoid arthritis: the patient perspective

Annals of the rheumatic diseases, 2005-10, Vol.64 (10), p.1456-1461

2005

Link zum Volltext

Verfügbarkeit prüfen

Gesundheitsökonomische Forschung im Bereich der chronischen Polyarthritis

Zeitschrift für Rheumatologie, 2002-02, Vol.61 (1), p.21-29

2002

Link zum Volltext

Verfügbarkeit prüfen

PHP156 - Recommendations In Clinical Guidelines, ‘No Benefit’ Ratings, And Opt-Out Decisions In Germany Since The Introduction Of The Amnog Law In 2011: How Do The Pieces Fit Together?

Value in health, 2016-11, Vol.19 (7), p.A466-A467

2016

Link zum Volltext

Verfügbarkeit prüfen

Recommendations In Clinical Guidelines, ‘No Benefit’ Ratings, And Opt-Out Decisions In Germany Since The Introduction Of The Amnog Law In 2011: How Do The Pieces Fit Together?

Value in health, 2016-11, Vol.19 (7), p.A466-A467

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(143)

Publikationsform

Sprache

Englisch
(128)
Deutsch
(25)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Humans
(40)
Life Sciences & Biomedicine
(34)
Arthritis, Rheumatoid - Economics
(18)
Biological And Medical Sciences
(18)
Rheumatology
(18)
Female
(17)
Male
(17)
Medical Sciences
(17)
Physical Sciences
(16)
Middle Aged
(15)
Adult
(14)
Germany
(14)
Physics Of Elementary Particles And Fields
(13)
Rheumatoid Arthritis
(13)
Aged
(12)
Beta Decay
(12)
Internal Medicine
(12)
Cost-Benefit Analysis
(11)
Diseases Of The Osteoarticular System
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: Whenever IQWiG and Federal Joint Committee disagree

Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?

The Risky Business of Drug Development: The Final Say of National Hta Agencies on A Pharmaceutical's Benefit During The Last Stretch of An Expensive, Long-Lasting And Arduous Development Journey – As Illustrated By The Decisions Of Germany's Gemeinsamer Bundesausschuss (G-Ba)

Dilemma of Cross-Over Trials and Their Impact on Benefit Assessment In Oncology

Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer’s data sources

PRM162 Appropriate Comparative Treatments for Early Benefit Assessment (EBA) in Germany. Comparing the Suggestions by the Joint Federal Committee (GBA) and the Pharmaceutical Companies

Comparison of Post-Authorisation Measures From Regulatory Authorities With Additional Evidence Requirements From HTA Bodies in Germany

Multi-Dimensional Capture of Patient-Relevant Endpoints in Regulatory Trials and Health Technology Assessments in Oncology Two Years After Introduction of the German Amnog Health Care Reform

PHP148 Early Benefit Assessment (EBA) in Germany: Differences Between Pharmaceutical Companies' Claims and IQWiG Benefit Assessments

PRM5 Attribution of Benefit to the Three Disease Dimensions Mortality, Morbidity, Quality of Life Within Early Benefit Assessment (EBA) in Germany

Content comparison of health status measures for obesity based on the international classification of functioning, disability and health

Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland

Development and validation of a self-administered systemic sclerosis questionnaire (SySQ)

Lipid-Lowering Medication for Secondary Prevention of Coronary Heart Disease in a German Outpatient Population: The Gap Between Treatment Guidelines and Real Life Treatment Patterns

Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland

PCN152 Patient-Relevant Endpoints (PRE) in Oncology - Current Issues in the Context of Early Benefit Assessment (EBA) in Germany: An Industry Perspective

Produktivitätskosten der rheumatoiden Arthritis in Deutschland : Kostenzusammensetzung und Prädiktion der Hauptkostenkomponenten

Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis

PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE

PDG84 REVIEW OF RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) AT THE EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUNETHTA)

Costs in rheumatology : results and lessons learned from the 'Hannover Costing Study'

Direct costs related to rheumatoid arthritis: the patient perspective

Gesundheitsökonomische Forschung im Bereich der chronischen Polyarthritis

PHP156 - Recommendations In Clinical Guidelines, ‘No Benefit’ Ratings, And Opt-Out Decisions In Germany Since The Introduction Of The Amnog Law In 2011: How Do The Pieces Fit Together?

Recommendations In Clinical Guidelines, ‘No Benefit’ Ratings, And Opt-Out Decisions In Germany Since The Introduction Of The Amnog Law In 2011: How Do The Pieces Fit Together?

Suchergebnisse filtern